Scientific MOOCs follower. Author of Airpocalypse, a techno-medical thriller (Out Summer 2017)

Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!

Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.

I am an early adopter of scientific MOOCs. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs? Imagine all the people sharing their data...

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC ( to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (

"Homo Sapiens is a profit-driven species"

"Personnellement je pense que la génomique pourrait à terme réduire le marché de la médecine réparatrice ... et cela ne doit pas plaire à certains ... il faut toujours essayer de comprendre pourquoi les gens disent ce qu'ils disent ... sachant que l'Homo Sapiens est guidé par son intérêt ..."

"My personal opinion is that genomic precision medicine will eventually disrupt replacement medicine... Now some people will embrace the change, some others won't, depending on where their interest lies. Homo Sapiens is a profit-driven species."

Jean-Michel Billaut, a French start-up validator.

Aucun commentaire: